Recent progress in sustained/controlled oral delivery of captopril: An overview

International Journal of Pharmaceutics

Volumn 194, Issue 2, 2000, Pages 139-146

  Nur, Abubakr O ^a   Zhang, Jun S ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Captopril; Controlled release; Dosage form; Sustained release

Indexed keywords

CAPTOPRIL;

CONGESTIVE HEART FAILURE; CONTROLLED DRUG RELEASE; DRUG FORMULATION; DRUG INDICATION; DRUG MANUFACTURE; DRUG RESEARCH; HUMAN; HYPERTENSION; PATENT; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; DELAYED-ACTION PREPARATIONS; HUMANS;

EID: 0033969822     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00362-2     Document Type: Review

References (41)

1. Abramowitz, R., Joshi Y.M., Jian, N.B., 1992. Captopril formulation providing increased duration of activity. US Patent 5158777, 27 Oct.
2. Anaizi N.H., Swenson C. Instability of captopril solution. Am. J. Hosp. Pharm. 50:1993;486-488.
3. Antonaccio M.J. Angiotensin converting enzyme (ACE) inhibitors. Ann. Rev. Pharmacol. Toxicol. 22:1982;57-87.
4. Bravo E.L., Tarazi R.C. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1:1979;39-46.
5. Brogen R.N., Todd P.A., Sorkin E.M. Captopril: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 36:1988;540-600.
6. Brunner H.R., Gavras H., Waebar B., Kershaw G.R., Turini G.A., Vukovish R.A., McKinstry D.N. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann. Intern. Med. 90:1979;19-23.
7. Deasy P.B., Brophy M.R., Ecanow B., Joy M.M. Effect of ethyl cellulose grade and sealant treatments on the production and in vitro release of microencapsulated sodium salicylate. J. Pharm. Pharmacol. 32:1984;15-20.
8. DeCrosta, M.T., Jain, N.B., Rudnic, E.M., 1987. Controlled release formulation. US Patent 4666705, 19 May.
9. Drost, J.D., Reier, G.E., Jain, N.B., 1988. Controlled release formulation. US patent 4756911, 12 Jul.
10. Duchin K.L., Singhvi S.M., Willard D.A., Migdalof B.H., McKinstry D.N. Captopril kinetics. Clin. Pharmacol. Ther. 31(4):1982;452-458.
11. Ferguson R.K., Brunner H.R., Turini G.A., Gavras H., McKinstry D.N. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1:1977;775-778.
12. Gavras H., Brunner H.R., Turini G.A., Kershaw G.R., Tifft C.P., Guttelod S., Gavras I., Vukovish R.A., McKinstry D.N. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14,225 in man. New Engl. J. Med. 298:1978;991-995.
13. Guittard, G.V., Carpenter, H.A., Quan, E.S., Wong, P.S., Hamel, L.G., 1993. Dosage form for delivering drug in short time period. US patent 5178867, 12 Jan.
14. Hu M., Amidon G.L. Passive and carrier-mediated intestinal absorption components of captopril. J. Pharm. Sci. 77(12):1988;1007-1011.
15. Ingani H.M., Timmermans J., Moes A.J. Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit. Int. J. Pharm. 35:1987;157-164.
16. Joshi, Y.M., Bachman, W.R., Jain, N.B., 1988. New pharmaceutical compositions in the form of beadlets and method. European Patent EP 288732 A2, 2 Nov.
17. Komai T., Ikeda T., Kawai K., Kameyama E., Shendo H. In-vitro studies on the metabolic pathway of SQ 14225 (captopril) and mechanism of disulfide formation. J. Pharmacobio-dynam. 4:1981;677-684.
18. Kripalani K.J., McKinstry D.N., Singhvi S.M., Willard D.N., Vukovish R.A., Migdalof B.H. Disposition of captopril in normal subjects. Clin. Pharmacol. Ther. 27(5):1980;636-641.
19. Lehr C.M., Bouwstra J.A., Kok W., Noach A.B.J., deBoer A.G., Junginger H.E. Bioadhesion by means of specific binding of tomato lectin. Pharm. Res. 9:1992;547-553.
20. Leung S.H.S., Robinson J.R. The contribution of anionic polymer structural features to mucoadhesion. J. Contr. Rel. 5:1988;223-231.
21. Longer M.A., Robinson J.R. Fundamental aspects of bioadhesion. Pharm. Int. 7:1986;114-117.
22. Martindale, 1996. The Extra Pharmacopoeia. Royal Pharmaceutical Society, thirty-first ed. London, pp. 838-839.
23. Matharu R.S., Singhavi N.M. Novel drug delivery system for captopril. Drug Dev. Ind. Pharm. 18(14):1992;1567-1574.
24. Miazaki N., Shionoiri H., Uneda S., Uneda G., Yasuda G., Gotoh E., Fujishima S., Kaneko Y., Kawahara Y., Yamazaki Y. Blood concentration and urinary excretion of captopril (SQ 14,225), angiotensin converting enzyme activity and R-A-A system after administration of captopril-in patient with chronic renal failure compared with essential hypertension. Nippon Jinzo Gakkai Shi. 24:1982;421-427.
25. Migdalof B.H., Wong K.K., Lan S.J., Kripalani K.J., Singhvi S.M. Evidence of dynamic interconversion of captopril and its disulfide metabolites in vivo. Fed. Proc. 39:1980;757-760.
26. Nahata M.C., Morosco R.S., Hipple T.F. Stability of captopril in three liquid dosage forms. Am. J. Hosp. Pharm. 51:1994;95-96.
27. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science. 196:1977;441-444.
28. Peppas N.A., Buri P.A. Surface, interfacial and molecular aspects of polymers bioadhesion on soft tissue. J. Contr. Rel. 2:1985;257-275.
29. Rashid, A., 1990. Dispensing device. British Patent Application 2230441A, 15 Feb.
30. Rowe R.C. The effect of molecular weight of ethyl cellulose on the drug release properties of mixed films of ethyl cellulose and hydroxypropyl methylcellulose. Int. J. Pharm. 29:1986;37-41.
31. Seta Y., Higuchi F., Kawahara Y., Nishimura K., Okada R. Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties. Int. J. Pharm. 41:1988;245-254.
32. Seta Y., Higuchi F., Otsuka T., Kawahara Y., Nishimura K., Okada R., Koike H. Preparation and pharmacological evaluation of captopril sustained-release dosage forms using oily semisolid matrix. Int. J. Pharm. 41:1988;255-262.
33. Seta Y., Otsuka T., Tokiwa H., Naganuma H., Kawahara Y., Nishimura K., Okada R. Design of captopril sustained-release preparation with oily semisolid matrix intended for use in human subjects. Int. J. Pharm. 41:1988;263-269.
34. Sheth P.R., Tossounian J. The hydrodynamically balanced system (HBSTM): a novel drug delivery system for oral use. Drug Dev. Ind. Pharm. 10(2):1984;313-339.
35. Singh J., Robinson D.H. Controlled release kinetics of captopril from tableted microcapsules. Drug Dev. Ind. Pharm. 14(4):1988;545-560.
36. Singhvi S.M., McKinstry D.N., Shaw J.M., Willard D.A., Migdalof B.H. Effect of food on the bioavailability of captopril in healthy subjects. J. Clin. Pharmacol. 22:1982;135-140.
37. Testa, M.A., Anderson, R.B., Nackley, J.F., Hollenberg, N.K., and the quality-of-life hypertension study group, 1993. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. New Engl. J. Med., 328, 907-913.
38. Thakur, A.B., Jain, N.B., 1988. Controlled release formulation and method. US patent 4738850, 19 Apr.
39. Wilding I.R., Davis S.S., Bakhshaee M., Stevens H.N., Sparrow R.A. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. Pharm. Res. 9(5):1992;654-657.
40. Wong K.K., Lan S.J., Migdalof B.H. The in vitro biotransformation of 14C-captopril in the blood of rats, dogs, and humans. Biochem. Pharmacol. 30:1980;2643-2650.
41. Worland P.J., Drummer O.H., Jarrott B. Gastric absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid. J. Pharm. Sci. 73(12):1984;1755-1758.